4.5 Article

Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer

期刊

NATURE MICROBIOLOGY
卷 1, 期 8, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/NMICROBIOL.2016.82

关键词

-

资金

  1. Helmut Horten Foundation
  2. Frederick National Laboratory for Cancer Research, National Institutes of Health [HHSN261200800001E]
  3. Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  4. Leidos Biomedical Research

向作者/读者索取更多资源

Human cytomegalovirus encodes at least 25 membrane glycoproteins that are found in the viral envelope(1). While gB represents the fusion protein, two glycoprotein complexes control the tropism of the virus: the gHgLgO trimer is involved in the infection of fibroblasts, and the gHgLpUL128L pentamer is required for infection of endothelial, epithelial and myeloid cells(2-5). Two reports suggested that gB binds to ErbB1 and PDGFRa (refs 6,7); however, these results do not explain the tropism of the virus and were recently challenged(8,9). Here, we provide a 19 angstrom reconstruction for the gHgLgO trimer and show that it binds with high affinity through the gO subunit to PDGFRa, which is expressed on fibroblasts but not on epithelial cells. We also provide evidence that the trimer is essential for viral entry in both fibroblasts and epithelial cells. Furthermore, we identify the pentamer, which is essential for infection of epithelial cells, as a trigger for the ErbB pathway. These findings help explain the broad tropism of human cytomegalovirus and indicate that PDGFRa and the viral gO subunit could be targeted by novel anti-viral therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year

Giulio Disanto, Alice Galante, Marco Cantu', Rosaria Sacco, Federico Mele, Jennifer Jessica Eisler, Franco Keller, Enos Bernasconi, Federica Sallusto, Chiara Zecca, Claudio Gobbi

Summary: This study investigated the longitudinal dynamics of SARS-CoV-2 antibodies and memory B cells in MS patients after vaccination, and their association with the risk of COVID-19. The results showed that certain treatments may decrease antibody levels and the production of memory B cells, increasing the risk of breakthrough infections.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Multidisciplinary Sciences

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

Roberta Marzi, Jessica Bassi, Chiara Silacci-Fregni, Istvan Bartha, Francesco Muoio, Katja Culap, Nicole Sprugasci, Gloria Lombardo, Christian Saliba, Elisabetta Cameroni, Antonino Cassotta, Jun Siong Low, Alexandra C. Walls, Matthew McCallum, M. Alejandra Tortorici, John E. Bowen, Exequiel A. Dellota, Josh R. Dillen, Nadine Czudnochowski, Laura Pertusini, Tatiana Terrot, Valentino Lepori, Maciej Tarkowski, Agostino Riva, Maira Biggiogero, Alessandra Franzetti-Pellanda, Christian Garzoni, Paolo Ferrari, Alessandro Cesch, Olivier Giannini, Colin Havenar-Daughton, Amalio Telenti, Ann Arvin, Herbert W. Virgin, Federica Sallusto, David Veesler, Antonio Lanzavecchia, Davide Corti, Luca Piccoli

Summary: We investigated the kinetics, avidity, and cross-reactivity of serum antibodies and memory B cells (MBCs) in SARS-CoV-2 infected and vaccinated individuals. Both infected and vaccinated individuals had steady-state titers of SARS-CoV-2-specific MBCs and serum antibodies with comparable kinetics. The maturation of high-affinity and broadly reactive MBCs provides the basis for effective recall responses to future SARS-CoV-2 variants, including Omicron BA.1 and BA.2 sublineages.

ISCIENCE (2023)

Article Biochemistry & Molecular Biology

Fibroblast, Epithelial and Endothelial Cell-Derived Human Cytomegalovirus Strains Display Distinct Neutralizing Antibody Responses and Varying Levels of gH/gL Complexes

Chiara Fornara, Eric Schultz, Daniele Lilleri, Fausto Baldanti, Brent Ryckman, Giuseppe Gerna

Summary: The serum neutralizing activity against HCMV varies depending on the producer cell type and the PC/TC ratio of virus preparations. The blocking activity of specific inhibitors also varies according to the PC/TC ratio. There is a potential producer cell effect on virus phenotype, but genetic factors cannot be overlooked. These findings have important implications for therapeutic antibodies and subunit vaccines.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Infectious Diseases

Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients

Benedict Fallet, Mathilde Foglierini, Raphael Porret, Ana Alcaraz-Serna, Christophe Sauvage, Raphael Jenelten, Teofila Caplanusi, Michel Gilliet, Laurent Perez, Craig Fenwick, Raphael Genolet, Alexandre Harari, Sara Bobisse, Raphael Gottardo, Giuseppe Pantaleo, Yannick D. Mueller

Summary: Intradermal skin test (IDT) with mRNA vaccines can be used to measure T cell response in immunocompromised patients who did not generate serological responses after vaccination. The study found that positive IDT reactions in immunocompromised patients were associated with B cell-depleting treatment, while negative reactions were observed in transplant recipients. This study provides a new method to monitor seronegative patients and elderly populations with waning immunity.

JOURNAL OF INFECTION (2023)

Article Multidisciplinary Sciences

A pan-influenza antibody inhibiting neuraminidase via receptor mimicry

Corey Momont, Ha V. V. Dang, Fabrizia Zatta, Kevin Hauser, Caihong Wang, Julia di Iulio, Andrea Minola, Nadine Czudnochowski, Anna De Marco, Kaitlin Branch, David Donermeyer, Siddhant Vyas, Alex Chen, Elena Ferri, Barbara Guarino, Abigail E. Powell, Roberto Spreafico, Samantha S. Yim, Dale R. Balce, Istvan Bartha, Marcel Meury, Tristan I. Croll, David M. Belnap, Michael A. Schmid, William Timothy Schaiff, Jessica L. Miller, Elisabetta Cameroni, Amalio Telenti, Herbert W. Virgin, Laura E. Rosen, Lisa A. Purcell, Antonio Lanzavecchia, Gyorgy Snell, Davide Corti, Matteo Samuele Pizzuto

Summary: The study describes a monoclonal antibody, FNI9, targeting neuraminidase, which can effectively inhibit the enzymatic activity of all group 1 and group 2 influenza A viruses, as well as certain influenza B viruses. FNI9 also shows broad neutralizing activity against seasonal influenza viruses and can synergize with antibodies targeting the hemagglutinin stem. The potent prophylactic activity of FNI9 against lethal influenza A and B virus infections in mice supports its development for the prevention of influenza illness.

NATURE (2023)

Editorial Material Cell Biology

Pandemic preparedness strategies must go beyond vaccines

Rajesh Gupta, Lisa A. Purcell, Davide Corti, Herbert W. Virgin

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Virology

Baseline Plasma Osteopontin Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients

Stelvio Tonello, Davide D'Onghia, Daria Apostolo, Erica Matino, Martina Costanzo, Giuseppe Francesco Casciaro, Alessandro Croce, Eleonora Rizzi, Erika Zecca, Anita Rebecca Pedrinelli, Veronica Vassia, Paolo Ravanini, Maria Grazia Crobu, Manuela Rizzi, Raffaella Landi, Luigi Mario Castello, Rosalba Minisini, Gian Carlo Avanzi, Mario Pirisi, Daniele Lilleri, Mattia Bellan, Donato Colangelo, Pier Paolo Sainaghi

Summary: This study aimed to evaluate osteopontin (OPN) as a potential biomarker for predicting the prognosis of COVID-19 patients. The results showed that higher plasma concentrations of OPN at hospital admission were associated with a worsening clinical condition. OPN levels might serve as a promising biomarker for early stratification of COVID-19 severity.

VIRUSES-BASEL (2023)

Article Cell Biology

Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail

Amin Addetia, Young -Jun Park, Tyler Starr, Allison J. Greaney, Kaitlin R. Sprouse, John E. Bowen, Sasha W. Tiles, Wesley C. Van Voorhis, Jesse D. Bloom, Davide Corti, Alexandra C. Walls, David Veesler

Summary: The evolution of SARS-CoV-2 is weakening antibody responses from vaccination and prior infection. The E406W mutation in the receptor-binding domain of the virus alters the epitopes recognized by therapeutic monoclonal antibodies and vaccine-induced neutralizing antibodies. This highlights the structural and functional plasticity of the SARS-CoV-2 RBD, which is continuously evolving in emerging variants.

CELL REPORTS (2023)

Article Microbiology

Inflammatory and Immune Responses during SARS-CoV-2 Infection in Vaccinated and Non-Vaccinated Pregnant Women and Their Newborns

Paola Zelini, Piera d'Angelo, Federica Zavaglio, Ehsan Soleymaninejadian, Liliana Mariani, Francesca Perotti, Mattia Dominoni, Stelvio Tonello, Pierpaolo Sainaghi, Rosalba Minisini, Daria Apostolo, Daniele Lilleri, Arsenio Spinillo, Fausto Baldanti

Summary: In this prospective study, it was found that vaccinated pregnant women and their newborns had higher levels of cytokines and immune responses after SARS-CoV-2 infection. Additionally, the newborns of vaccinated mothers had higher levels of specific antibodies. Vaccination can enhance the immune profile of pregnant women and provide immune protection to newborns.

PATHOGENS (2023)

Article Biology

Myc controls NK cell development, IL-15-driven expansion, and translational machinery

Hanif J. Khameneh, Nicolas Fonta, Alessandro Zenobi, Charlene Niogret, Pedro Ventura, Concetta Guerra, Ivo Kwee, Andrea Rinaldi, Matteo Pecoraro, Roger Geiger, Andrea Cavalli, Francesco Bertoni, Eric Vivier, Andreas Trumpp, Greta Guarda

Summary: This study reveals the importance of MYC in NK cells and its role in regulating translation and expansion, as well as anticancer immunity. Deficiency of MYC in NK cells results in reduced numbers and impaired cytotoxic functions of mature NK cells.

LIFE SCIENCE ALLIANCE (2023)

Article Gastroenterology & Hepatology

Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice

Florian A. Lempp, Tassilo Volz, Elisabetta Cameroni, Fabio Benigni, Jiayi Zhou, Laura E. Rosen, Julia Noack, Fabrizia Zatta, Hannah Kaiser, Siro Bianchi, Gloria Lombardo, Stefano Jaconi, Lucia Vincenzetti, Hasan Imam, Leah B. Soriaga, Nadia Passini, David M. Belnap, Andreas Schulze, Marc Luetgehetmann, Amalio Telenti, Andrea L. Cathcart, Gyorgy Snell, Lisa A. Purcell, Christy M. Hebner, Stephan Urban, Maura Dandri, Davide Corti, Michael A. Schmid

Summary: This study describes a monoclonal antibody that targets the surface antigen of hepatitis B virus (HBV) and shows potential for treating chronic hepatitis B and chronic hepatitis D. The antibody effectively neutralizes HBV and HDV infections in vitro and reduces viral levels in human liver-chimeric mice.

JOURNAL OF HEPATOLOGY (2023)

Article Infectious Diseases

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Craig Fenwick, Priscilla Turelli, Yoan Duhoo, Kelvin Lau, Cecile Herate, Romain Marlin, Myriam Lamrayah, Jeremy Campos, Line Esteves-Leuenberger, Alex Farina, Charlene Raclot, Vanessa Genet, Flurin Fiscalini, Julien Cesborn, Laurent Perez, Nathalie Dereuddre-Bosquet, Vanessa Contreras, Kyllian Lheureux, Francis Relouzat, Rana Abdelnabi, Pieter Leyssen, Yves Levy, Florence Pojer, Roger Le Grand, Didier Trono, Giuseppe Pantaleo

Summary: This study isolated a potent neutralizing antibody that can neutralize various variants of SARS-CoV-2 and potentially provide prophylactic protection for immunocompromised patients.

JOURNAL OF INFECTION (2023)

Article Multidisciplinary Sciences

Neutralization, effector function and immune imprinting of Omicron variants

Amin Addetia, Luca Piccoli, James Brett Case, Young-Jun Park, Martina Beltramello, Barbara Guarino, Ha Dang, Guilherme Dias de Melo, Dora Pinto, Kaitlin Sprouse, Suzanne M. Scheaffer, Jessica Bassi, Chiara Silacci-Fregni, Francesco Muoio, Marco Dini, Lucia Vincenzetti, Rima Acosta, Daisy Johnson, Sambhavi Subramanian, Christian Saliba, Martina Giurdanella, Gloria Lombardo, Giada Leoni, Katja Culap, Carley Mcalister, Anushka Rajesh, Exequiel Dellota, Jiayi Zhou, Nisar Farhat, Dana Bohan, Julia Noack, Alex Chen, Florian A. Lempp, Joel Quispe, Lauriane Kergoat, Florence Larrous, Elisabetta Cameroni, Bradley Whitener, Olivier Giannini, Pietro Cippa, Alessandro Ceschi, Paolo Ferrari, Alessandra Franzetti-Pellanda, Maira Biggiogero, Christian Garzoni, Stephanie Zappi, Luca Bernasconi, Min Jeong Kim, Laura E. Rosen, Gretja Schnell, Nadine Czudnochowski, Fabio Benigni, Nicholas Franko, Jennifer K. Logue, Courtney Yoshiyama, Cameron Stewart, Helen Chu, Herve Bourhy, Michael A. Schmid, Lisa A. Purcell, Gyorgy Snell, Antonio Lanzavecchia, Michael S. Diamond, Davide Corti, David Veesler

Summary: The recently emerged BQ.1.1 and XBB.1.5 variants of SARS-CoV-2 have a higher affinity for the host ACE2 receptor and more efficiently promote fusion with host cell membranes compared to earlier Omicron variants. Although the neutralizing activity is reduced, vaccine-induced human plasma antibodies still cross-react with and trigger effector functions against current Omicron variants, providing a mechanism of protection against disease.

NATURE (2023)

Article Immunology

Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy

Maira Zorzan, Martina Castellan, Matteo Gasparotto, Guilherme Dias de Melo, Barbara Zecchin, Stefania Leopardi, Alex Chen, Antonio Rosato, Alessandro Angelini, Herve Bourhy, Davide Corti, Laura Cendron, Paola De Benedictis

Summary: Rabies is a fatal disease caused by lyssaviruses, with rabies virus (RABV) being the most prevalent and important. Two neutralizing monoclonal antibodies (mAbs), RVC20 and RVC58, have shown efficacy in treating symptomatic rabies. Structural modeling and in vitro assays revealed that both mAbs recognize and lock the RABV-G protein in its pre-fusion conformation. RVC58 exhibited stronger neutralization of extracellular virus, while RVC20 mainly reduced viral spreading from infected cells. Additionally, RVC20 was more effective in promoting effector functions compared to 17C7-RAB1 mAb. These findings provide valuable insights for the development of mAb treatments for human rabies.

FRONTIERS IN IMMUNOLOGY (2023)

Letter Urology & Nephrology

Prevalence of SARS-CoV-2 infection and impact of vaccination in dialysis patients over two years of the pandemic

Paolo Hitz, Alberto Pagnamenta, Laura Pertusini, Tatiana Terrot, Yves Franzosi, Jessica Bassi, Chiara Silacci-Fregni, Valeria Gaia, Gladys Martinetti, Franco Keller, Lorenzo Berwert, Valentina Forni Ogna, Soraya Lavorato-Hadjeres, Davide Giunzioni, Andrea D'Ermo, Alan Valnegri, Paolo Ferrari, Davide Corti, Alessandro Ceschi, Pietro Cippa, Luca Piccoli, Olivier Giannini

JOURNAL OF NEPHROLOGY (2023)

暂无数据